	US 11,911,465 B2
	Vaccine compositions and methods of use
Frank Bedu-Addo, Bethel, CT (US); Eric Jacobson, Cincinnati, OH (US); and Kenya Johnson, Mason, OH (US)
Assigned to PDS Biotechnology Corporation, North Brunswick, NJ (US)
Filed by PDS BIOTECHNOLOGY CORPORATION, North Brunswick, NJ (US)
Filed on Jul. 22, 2021, as Appl. No. 17/383,378.
Application 17/383,378 is a continuation of application No. 16/388,291, filed on Apr. 18, 2019.
Application 16/388,291 is a continuation of application No. 14/429,123, abandoned, previously published as PCT/US2013/061132, filed on Sep. 23, 2013.
Claims priority of provisional application 61/703,814, filed on Sep. 21, 2012.
Prior Publication US 2021/0361766 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 39/12 (2006.01); A61K 39/02 (2006.01); A61K 39/145 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/39 (2013.01) [A61K 39/0002 (2013.01); A61K 39/0005 (2013.01); A61K 39/02 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/70 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16234 (2013.01); Y02A 50/30 (2018.01)]

12 Claims

1. A method of effecting antigen cross presentation to induce a humoral immune response and a CD 8+ T cell response in a mammal, said method comprising the step of administering an effective amount of a vaccine composition to the mammal, wherein the vaccine composition comprises a lipid and at least one multi-epitope viral antigen, wherein the lipid consists of a cationic lipid, and wherein the cationic lipid consists of R-DOTAP, and wherein the CD 8+ T-cell response is enhanced by at least 2-fold over that elicited by the viral antigen alone.